BioNTech presents an overview of its AI approach during an edition of the Company’s Innovation Series, AI Day. “At BioNTech, we are at the forefront of integrating advanced AI to revolutionize individualized medicine. With our in-house AI specialist, InstaDeep, we are pioneering the use of artificial intelligence to develop personalized vaccines and targeted therapies,” said Prof. Ugur Sahin, M.D., CEO and Co-Founder of BioNTech. “By introducing state-of-the-art technologies such as our BFN generative protein model and incorporating AI capabilities across our immunotherapy pipeline, we are unlocking the full potential of AI to deliver innovative vaccines and cancer treatments to patients worldwide”. As part of the event, BioNTech will showcase the Company’s approach to AI capability scaling and deployment across BioNTech’s pipeline. These updates will cover the introduction of a new near exascale supercomputer, the launch of a novel BFN generative model, and multiple updates on the deployment of AI across BioNTech’s immunotherapy pipeline.
Don't Miss our Black Friday Offers:
- Unlock your investing potential with TipRanks Premium - Now At 40% OFF!
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BNTX:
- Pfizer, BioNTech updated COVID vaccine authorized in Canada
- Walmart upgraded, Starbucks downgraded: Wall Street’s top analyst calls
- BioNTech upgraded to Overweight from Equal Weight at Morgan Stanley
- Morgan Stanley upgrades BioNTech on cancer potential of BNT327
- BioNTech’s Omicron Vaccine Awaits EU Approval